<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Introduction</h3><p>Gene therapy for haemophilia is in late-stage clinical development and has the potential to become a therapeutic option in clinical practice.</p></sec>
<sec><h3>Aims</h3><p>To enhance the understanding of the perspectives of people with haemophilia around gene therapy, and to highlight their concerns about and motivations for having gene therapy.</p></sec>
<sec><h3>Method</h3><p>Structured, qualitative interviews were conducted and recorded with six people who had received an investigational gene therapy product. The recordings were transcribed and thematically analysed.</p></sec>
<sec><h3>Results</h3><p>Most of those interviewed were under the age of 40, and the mean time out from their gene therapy infusion was 10 months. Adverse events were the main concerns pre-infusion, and impact on quality of life was the main motivating factor for choosing to go ahead. Pre-infusion, the treating centre and the health care professionals working there were the main source of information regarding gene therapy; only two participants looked elsewhere for information to support their decision. None of the respondents expressed concerns about the infusion day itself, and all found the infusion to be simple or uneventful. Post-infusion, four found the frequency of follow-up appointments difficult, with time and travel the main issues.</p></sec>
<sec><h3>Conclusion</h3><p>Although participants' perspectives on gene therapy were generally positive, there remains a need for education and support. Nurses will play an important role in the delivery of gene therapy for haemophilia, but all staff within the haemophilia treatment centre should be armed with the knowledge and confidence to answer questions about gene therapy.</p></sec>
</abstract>

IntroductionGene therapy for haemophilia is in late-stage clinical development and has the potential to become a therapeutic option in clinical practice.
AimsTo enhance the understanding of the perspectives of people with haemophilia around gene therapy, and to highlight their concerns about and motivations for having gene therapy.
MethodStructured, qualitative interviews were conducted and recorded with six people who had received an investigational gene therapy product. The recordings were transcribed and thematically analysed.
ResultsMost of those interviewed were under the age of 40, and the mean time out from their gene therapy infusion was 10 months. Adverse events were the main concerns pre-infusion, and impact on quality of life was the main motivating factor for choosing to go ahead. Pre-infusion, the treating centre and the health care professionals working there were the main source of information regarding gene therapy; only two participants looked elsewhere for information to support their decision. None of the respondents expressed concerns about the infusion day itself, and all found the infusion to be simple or uneventful. Post-infusion, four found the frequency of follow-up appointments difficult, with time and travel the main issues.
ConclusionAlthough participants' perspectives on gene therapy were generally positive, there remains a need for education and support. Nurses will play an important role in the delivery of gene therapy for haemophilia, but all staff within the haemophilia treatment centre should be armed with the knowledge and confidence to answer questions about gene therapy.

The patient gene therapy journey: Findings from qualitative interviews with trial participants at one UK haemophilia centre

Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust

The Journal of Haemophilia Practice

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

IntroductionGene therapy for haemophilia is in late-stage clinical development and has the potential to become a therapeutic option in clinical...

The patient gene therapy journey: Findings from qualitative interviews with trial participants at one UK haemophilia centre

Article Category: Clinical Research

Publié en ligne: 02 mai 2021

Pages: 32 - 44

DOI: https://doi.org/10.17225/jhp00174

Mots clés
gene therapy, haemophilia, experience, views of people with haemophilia, nurse

© 2021 Elsa Aradom et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Figure 3

The patient gene therapy journey: Findings from qualitative interviews with trial participants at one UK haemophilia centre

Article Category: Clinical Research

Publié en ligne: 02 mai 2021

Pages: 32 - 44

DOI: https://doi.org/10.17225/jhp00174

Mots clésgene therapy, haemophilia, experience, views of people with haemophilia, nurse

© 2021 Elsa Aradom et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Figure 3

Mots clés
gene therapy, haemophilia, experience, views of people with haemophilia, nurse